Table 1.
Summary of the methodological characteristics of the included studies.
| Registry | Study name | Study duration | Year of entry | Study country | Number of patients included | Biologic- naive (%) |
|---|---|---|---|---|---|---|
| Biologic-naive | ||||||
| DREAM | Flendrie et al. 2003 [1] | Maximum follow-up time for ADA, INF, and ETN was 69 months, 35 months, and 30 months, respectively. | ADA was started between April 1997 and September 2000, INF was started since January 2000, and ETN was started since February 2000 | The Netherlands | 230 | 100 |
| SCQM | Genta et al. 2006 [2] | 38 month-follow-up | Before February 2003 | Switzerland | 66 | 100 |
| DANBIO | Hetland et al. 2010 [3] | The median (IQR) follow-up times were as follows: for ADA, 20 months (IQR: 7 months–39 months); for ETN, 21 months (IQR: 9 months–42 months); and for INF, 16 months (IQR: 5 months–36 months) | October 2000 to 31 December 2007 | Denmark | 2326 | 100 |
| BSRBR | Hyrich et al. 2007 [4] | The mean length of follow-up per patient was 15 months (maximum 61 months) | Patients who completed minimum 6 months of follow-up by the end of April 2005 | UK | 6739 | 100 |
| GISEA | Iannone et al. 2011 [5] | 48 months | 2003-2004 | Italy | 853 | 100 |
| DREAM | Kievit et al. 2007 [6] | Mean follow-up duration was 20 months for INF cohort and 13 months for ETN and ADA cohorts | April 2003 to December 2005 | The Netherlands | 546 | 100 |
| DREAM | Kievit et al. 2008 [7] | 12 months | February 2003 to August 2007 | The Netherlands | 707 | 100 |
| LOHREN | Marchesoni et al. 2009 [8] | 36 months | 1999 | Italy | 1064 | 100 |
| BSRBR | Hyrich et al. 2006 [9] | 6 months (minimum follow-up duration) | Only those patients who had reached six month follow-up prior to 1 October 2004 were included | UK | 3223 | 100 |
| BSRBR | Hyrich et al. 2006b [10] | 6 months | Not reported | UK | 2711 | 100 |
| DANBIO | Østergaard et al. 2007 [11] | Not reported | Before October 2002 | Denmark | 417 | 100 |
|
| ||||||
| Mixed (biologic pretreated and biologic-naive) | ||||||
| SCQM | Finckh et al. 2006 [12] | The median follow-up time for ADA, INF, and ETN was 10.7 months (IQR: 5.8 months–12.3 months), 18.8 months (IQR: 11.5 months–28.3 months), and 23.7 months (IQR: 12.6 months–35.8 months), respectively. | Between January 1998 and September 2004 | Switzerland | 1198 | 83 |
| SCQM | Pan et al. 2009 [13] | Not reported | January 1997 to December 2006 | Switzerland | 2364 | 77 |
| RABBIT | Strangfeld et al. 2009 [14] | 36 months | 1 May 2001 to 31 December 2006 | Germany | 1769 | 81 |
| RABBIT | Zink et al. 2006 [15] | 12 months | Between May 1 2001 and December 31 2004 | Germany | 1458 | 78.3 |
| RABBIT | Zink et al. 2005 [16] | Not reported | Patients enrolled between May 2001 and September 2003, were included and followed up to March 2004. | Germany | 1523 | 87.9 |
ARTIS: Antirheumatic Therapies in Sweden; ATTRA: Anti-TNF treatment of rheumatoid arthritis; BIOBADASER: Base de Datos de Productos Biológicos de la Sociedad Española de Reumatología; BSRBR: British Society for Rheumatology Biologics Register; DANBIO: Danish Biologic Registry; DAS: disease activity score; DMARDs: disease-modifying antirheumatic drugs; DREAM: Dutch Rheumatoid Arthritis Monitoring; EMECAR: Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide; GISEA: Italian Group for the Study of Early Arthritis; LOHREN: Lombardy Rheumatology Network; NOR-DMARD: Norwegian Disease-modifying antirheumatic Drugs; RABBIT: rheumatoid arthritis observation of biologic therapy; RA: rheumatoid arthritis; RATIO: French Research Axed on Tolerance of Biotherapies; ROB-FIN: Register of Biological Treatment in Finland; SCQM: Swiss Clinical Quality Management in Rheumatic Diseases; SSATG: Southern Sweden Antirheumatic Therapy Group; STURE: Stockholm Tumour Necrosis Factor-α Follow-up Registry; TNF: tumour necrosis factor; UK: United Kingdom.